Nasdaq: ALKS+7.13% 24h move
Price before$35.47May 11, 2026, 4:00 PM ET
First trade after$35.70May 12, 2026, 7:17 AM ET
24h later$38.00May 12, 2026, 4:44 PM ET
Complete Announced during: Premarket · announced Tue 7:07a ET (premarket); before = Mon close; first trade Tue 7:17a ET; time = SEC 8-K acceptance
Alkermes (Nasdaq: ALKS) reported topline results from a Phase 3 trial of LUMRYZ in idiopathic hypersomnia on May 12, 2026. The company said the trial met its primary endpoint (p<0.0001).
Trial details
- Drug
- LUMRYZ
- Treats
- Idiopathic Hypersomnia
- Phase
- Phase 3
- Result
- Met endpointLUMRYZ met the study’s primary endpoint, demonstrating statistically significant improvements in excessive daytime sleepiness compared to placebo as measured by the change in Epworth Sleepiness Scale (ESS)1 score (p<0.0001).p-value p<0.0001Figures as reported by the sponsor or registry; not calculated by DrugTrials.org.
- Safety
- The safety profile of LUMRYZ in the REVITALYZ study was generally consistent with previously observed safety data associated with LUMRYZ, with no new safety signals observed in this population.
- Sponsor
- Alkermes Nasdaq: ALKS
- Dates
- Announced May 12, 2026, 7:07 AM ET (SEC 8-K filing time)
About this trial
This Phase 3 trial tested LUMRYZ in Idiopathic Hypersomnia. Alkermes reported that the trial met its primary endpoint (p-value: p<0.0001).
Sources
- Source: SEC EDGAR 8-K (EX-99.1)
For information only. Not investment or medical advice. Prices are historical, from consolidated market data, and may contain errors. Always check the original source.